BACKGROUND: As we are in the middle of the second year of the COVID19 Pandemic,we are observing an increased
incidence of conditions like Cerebrovascular Accidents, Ischemic Heart Disease, Myocardial Infarction, Deep Vein
Thrombosis,Pulmonary Embolism,and Thrombosis of Other Vessels.
MATERIALS AND METHODS: Literature Review and Analysis of Coagulation Profiles of Patients in the past 1 year
treated by the author was done.
RESULTS AND CONCLUSIONS:
1. COVID19 is not just an infectious disease, but also an Immune Disease. The Immune Part can also happen in
Asymptomatic Patients and those who got the vaccine.
2. Most of the disease processes in the body start after the virus has been cleared from the throat. The vigil against
complications must not stop when the Throat Swab becomes negative or even when the patient is discharged but
must continue for months till all the disease processes stop.
3.It is recommended that:
a.Initial Evaluation with PT, aPTT, INR is done for:
I.Those suffering from COVID 19 who have not undergone D Dimer evaluation
ii.Those recovering from COVID 19.
iii.Those likely to have had COVID 19 (based on the symptoms),but the infection was not documented.
iv.Those likely to have had asymptomatic COVID 19 (contacts of COVID19 infected patients)
v.Those planning to take Vaccines for COVID19.
b.An Abnormal Value in PT,aPTT,INR may be managed with appropriate Drugs like Aspirin,Clopidogrel,Dipyridamole,
Ticlopidine, Rivaroxaban, Dabigatran, Apixaban, Edoxaban, Heparin, Low Molecular Weight Heparin, Warfarin, and
other drugs.
c. Serial Evaluation of PT, aPTT, INR be done after 1 month, 3 months, 6 months (and even at more frequent intervals if
indicated) and the drugs are added or removed,the dosage of the drugs is increased or reduced based on the results.
d.Standard Indication of IVC Filter may be followed.
4.It is the knowledge of the pathogenesis of Thrombosis that is crucial in the prevention and management of Stroke,
Heart Attack, Deep Vein Thrombosis, and Pulmonary Embolism rather than fancy gadgets, expensive tests, and
exotic drugs.
Potential impact of oral contraceptive choice on myocardial infarction mortality and deep vein thrombosis